Literature DB >> 32497334

A missing link between SARS-CoV-2 and the eye?: ACE2 expression on the ocular surface.

Rafael S Grajewski1, Alexander C Rokohl1, Martina Becker1, Felix Dewald2, Clara Lehmann3, Gerd Fätkenheuer3, Claus Cursiefen1, Florian Klein2, Ludwig M Heindl1,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32497334      PMCID: PMC7300893          DOI: 10.1002/jmv.26136

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
Dear Editor, We applaud Lange et al for their extensive efforts to analyze entry factors for severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) into conjunctival epithelial cells covering the ocular surface, which is an important albeit controversially discussed issue. , In this journal, Lange et al using high‐throughput RNA sequencing and immunohistochemistry could not find any significant expression of angiotensin converting enzyme (ACE2) in the conjunctiva. In contrast, Sungnak et al recently demonstrated expression of ACE2 in the epithelium but not in the stroma of human conjunctiva using single‐cell RNA‐sequencing. This is a clinically highly relevant and urgent issue, since conjunctivitis has been reported as an ocular manifestation of coronavirus disease 2019 (COVID‐19) , , and tears have the potential to spread the infection by draining into the nasopharynx through the naso‐lacrimal system. Here, using the same anti ACE2‐antibody as Lange et al under modified experimental conditions (basic instead of acidic antigen retrieval buffer, different dilution and incubation period of primary antibody) we could clearly demonstrate ACE2 expression in the conjunctiva by immunohistochemistry, as determined by Sungnak et al on a RNA level (Figure 1). After obtaining written informed consent, ACE2 was, for the first time to our knowledge, detected in formalin fixed paraffin‐embedded sections of healthy human conjunctiva using mouse anti‐human ACE2 monoclonal antibody (catalog #MAB933, monoclonal mouse IgG2a anti‐human ACE2, clone #171606; dilution 1:100; R&D Systems) at 5 μg/mL for 60 minutes at room temperature. Before incubation with the primary antibody, tissue was subjected to heat‐induced epitope retrieval using Target Retrieval Solution pH 9 (catalog #S2367; Dako). Tissue was stained using DCS DetectionLine, Polylink and Peroxidase Label Horseradish Peroxidase(catalog #PD000RP; DCS) and as the substrate chromogen AEC + High Sensitivity (catalog #K3461; DakoCytomation). The counterstain was hematoxylin (blue). Staining revealed immunopositivity specifically confined to the conjunctival epithelium (Figure 1A). The conjunctival stroma was devoid of ACE2 immunopositivity (Figure 1A). Healthy human conjunctiva sections of seven other patients revealed ACE2 immunopositivity of the epithelium in all samples. Three of these eight patients (age range 8 weeks to 78 years, median age 56 years) were healthy, including the patient in Figure 1A‐C (age 43 years), four had arterial hypertension that was treated with ACE inhibitors or ACE‐II‐receptor antagonists. Although we did not see a relation of ACE2 expression to these and other clinical parameters, the sample size is too small for definitive conclusions.
Figure 1

Angiotensin converting enzyme (ACE2) is expressed in healthy human conjunctiva

Angiotensin converting enzyme (ACE2) is expressed in healthy human conjunctiva Staining both without the primary antibody (Figure 1B) as well as an isotype control (Figure 1C; monoclonal mouse immunoglobulin 2a [IgG2a] antibody, clone #20102; dilution 1:100; R&D Systems) demonstrated no staining. Human kidney tissue served as a positive control and showed a specific staining of epithelial cells in convoluted tubules (Figure 1D; NO primary antibody: E, isotype control: F). Human skin served as a negative control (Figure 1H‐J, respectively). The location of ACE2 expression at the ocular surface enables direct contact of SARS‐CoV‐2 with conjunctival cells, raising the question how often this occurs and if protective mechanisms of tears and conjunctiva might prevent conjunctivitis to happen more frequently. For example, it has to be taken into account that people are breathing in many litres of air potentially containing many viral particles that can be distributed on the huge mucosal surface of the airways and the lung. In contrast, the much smaller mucosal surface of the conjunctiva might only accidentally be hit by single particles, except when contagious aerosols are being blown or coughed directly into the face. Also, tears might contain antiviral substances such as interferons. Furthermore, it is not clear, whether isolated conjunctivitis may occur without concurrent organ manifestation such as pneumonia, as suggested by current studies, since patients without other symptoms than conjunctivitis are not routinely tested for SARS‐CoV‐2. Ophthalmologists and eye‐care personnel have been described at risk for transmission of COVID‐19 due to close contact to patients during examination. In summary, our results provide an important addition to the results of Lange et al and other works by clearly demonstrating specific ACE2 expression in conjunctival epithelial cells, providing the receptor for direct entry of SARS‐CoV‐2. Together, these findings emphasize the urgent need for further research regarding the eye as a possible alternative route for transmission of SARS‐CoV‐2.

FUNDING INFORMATION

German Research Foundation (FOR 2242 “(Lymph) Angiogenesis And Cellular Immunity In Inflammatory Diseases Of The Eye” to LMH (HE 6743/2‐1 and 3‐1 to LMH)

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.
  6 in total

1.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.

Authors:  Waradon Sungnak; Ni Huang; Christophe Bécavin; Marijn Berg; Rachel Queen; Monika Litvinukova; Carlos Talavera-López; Henrike Maatz; Daniel Reichart; Fotios Sampaziotis; Kaylee B Worlock; Masahiro Yoshida; Josephine L Barnes
Journal:  Nat Med       Date:  2020-04-23       Impact factor: 53.440

2.  Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection.

Authors:  Jianhua Xia; Jianping Tong; Mengyun Liu; Ye Shen; Dongyu Guo
Journal:  J Med Virol       Date:  2020-03-12       Impact factor: 2.327

3.  Revisiting the dangers of the coronavirus in the ophthalmology practice.

Authors:  Ivan Seah; Xinyi Su; Gopal Lingam
Journal:  Eye (Lond)       Date:  2020-02-06       Impact factor: 3.775

Review 4.  Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals.

Authors:  Ivan Seah; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2020-03-16       Impact factor: 3.070

5.  Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients.

Authors:  Ivan Yu Jun Seah; Danielle E Anderson; Adrian Eng Zheng Kang; Linfa Wang; Pooja Rao; Barnaby Edward Young; David Chien Lye; Rupesh Agrawal
Journal:  Ophthalmology       Date:  2020-03-24       Impact factor: 12.079

6.  Expression of the COVID-19 receptor ACE2 in the human conjunctiva.

Authors:  Clemens Lange; Julian Wolf; Claudia Auw-Haedrich; Anja Schlecht; Stefaniya Boneva; Thabo Lapp; Ralf Horres; Hansjürgen Agostini; Gottfried Martin; Thomas Reinhard; Günther Schlunck
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

  6 in total
  18 in total

Review 1.  COVID-19 and the eye: alternative facts The 2022 Bowman Club, David L. Easty lecture.

Authors:  Lawson Ung; James Chodosh
Journal:  BMJ Open Ophthalmol       Date:  2022-05

2.  Tracing the SARS-CoV-2 infection on the ocular surface: Overview and preliminary corneoscleral transcriptome sequencing.

Authors:  Umberto Rosani; Claudia Del Vecchio; Elisa Franchin; Paola Brun; Stefano Ferrari; Diego Ponzin; Andrea Leonardi
Journal:  Exp Eye Res       Date:  2022-02-05       Impact factor: 3.770

Review 3.  [What is the importance of the conjunctiva as a potential transmission pathway for SARS-CoV-2 infections?]

Authors:  Clemens Lange; Julian Wolf; Claudia Auw-Haedrich; Anja Schlecht; Stefaniya Boneva; Thabo Lapp; Hansjürgen Agostini; Gottfried Martin; Thomas Reinhard; Günther Schlunck
Journal:  Ophthalmologe       Date:  2020-07       Impact factor: 1.059

4.  The SARS-CoV-2, tears, and ocular surface debate: What we know and what we need to know.

Authors:  Mohammad Javed Ali
Journal:  Indian J Ophthalmol       Date:  2020-07       Impact factor: 1.848

5.  Malignancy going viral: ACE2 and TMPRSS2 expression in conjunctival neoplastic diseases.

Authors:  Rafael S Grajewski; Alexander C Rokohl; Martina Becker; Friedrich Paulsen; Ludwig M Heindl
Journal:  Ann Anat       Date:  2020-12-17       Impact factor: 2.698

Review 6.  What is the significance of the conjunctiva as a potential transmission route for SARS-CoV-2 infections?

Authors:  Clemens Lange; Julian Wolf; Claudia Auw-Haedrich; Anja Schlecht; Stefaniya Boneva; Thabo Lapp; Hansjürgen Agostini; Gottfried Martin; Thomas Reinhard; Günther Schlunck
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

Review 7.  Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.

Authors:  Luca Perico; Ariela Benigni; Federica Casiraghi; Lisa F P Ng; Laurent Renia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2020-10-19       Impact factor: 28.314

8.  The Physical and Psychological Effects of Personal Protective Equipment on Health Care Workers in Wuhan, China: A Cross-Sectional Survey Study.

Authors:  Wei Xia; Lin Fu; Haihan Liao; Chan Yang; Haipeng Guo; Zhouyan Bian
Journal:  J Emerg Nurs       Date:  2020-09-29       Impact factor: 1.836

9.  More than loss of taste and smell: burning watering eyes in coronavirus disease 2019.

Authors:  Alexander C Rokohl; Niklas Loreck; Philomena A Wawer Matos; Sarah Zwingelberg; Max Augustin; Felix Dewald; Rafael S Grajewski; Florian Klein; Clara Lehmann; Ludwig M Heindl
Journal:  Clin Microbiol Infect       Date:  2020-08-21       Impact factor: 13.310

10.  Ocular findings in patients with coronavirus disease 2019 (COVID-19) in an outbreak hospital.

Authors:  Hasan Öncül; Fatma Y Öncül; Mehmet F Alakus; Mehtap Çağlayan; Umut Dag
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.